Research Topics
| D M BlackSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosisD M Black
Department of Epidemiology and Biostatistics, University of California, San Fransisco, Suite 5700, 185 Berry Street, San Francisco, CA 94107, USA
Osteoporos Int 24:1503-11. 2013..The purpose of this study is to examine the effect of PTH(1-84) treatment over 24 months followed by 12 months discontinuation on BMD, bone turnover markers, fractures and the impact of adherence on efficacy...
Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fracturesNicola Napoli
Università Campus Bio Medico di Roma, 83 00155 Rome, Italy
J Clin Endocrinol Metab 98:659-67. 2013..However, the incidence and risk factors associated with these fractures have not been well defined...- Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fracturesNicola Napoli
Università Campus Bio Medico di Roma, Roma, Italy
J Clin Endocrinol Metab 97:2414-22. 2012.... - The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)Dennis M Black
Department of Epidemiology and Biostastistics, University of California, San Francisco, CA 94107, USA
J Bone Miner Res 27:243-54. 2012..However, vertebral fracture reductions suggest that those at high fracture risk, particularly vertebral fracture, may benefit by continued treatment... - Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCTDennis M Black
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California 94107, USA
J Bone Miner Res 23:1326-33. 2008.... - Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodelingDennis M Black
Department of Epidemiology and Biostatistics, University of California San Francisco, 185 Berry Street, San Francisco, CA 94107, USA
J Clin Endocrinol Metab 93:2166-72. 2008..Daily PTH administration increases bone mineral density (BMD) and reduces fracture risk. However, cost and compliance significantly limit clinical use... 
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosisDennis M Black
University of California, San Francisco, San Francisco, CA 94107, USA
N Engl J Med 356:1809-22. 2007..We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period...- Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trialDennis M Black
San Francisco Coordinating Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94107, USA
JAMA 296:2927-38. 2006..The optimal duration of treatment of women with postmenopausal osteoporosis is uncertain... - Bisphosphonates and fractures of the subtrochanteric or diaphyseal femurDennis M Black
University of California at San Francisco, San Francisco, CA 94107, USA
N Engl J Med 362:1761-71. 2010..A population-based study did not support this association. Such a relationship has not been examined in randomized trials... - The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisDennis M Black
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94105, USA
N Engl J Med 349:1207-15. 2003..We conducted a randomized, double-blind clinical study of parathyroid hormone and alendronate to test the hypothesis that the concurrent administration of the two agents would increase bone density more than the use of either one alone... - One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosisDennis M Black
Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94105, USA
N Engl J Med 353:555-65. 2005..In the continuation of this trial, we asked whether antiresorptive therapy is required to maintain gains in bone mineral density after one year of therapy with parathyroid hormone (1-84)... - An assessment tool for predicting fracture risk in postmenopausal womenD M Black
Department of Epidemiology and Biostatistics, University of California, San Francisco 94105, USA
Osteoporos Int 12:519-28. 2001.... - A normative reference database study for Pronosco X-posure SystemD M Black
University of California, San Francisco, CA 94106, USA
J Clin Densitom 4:5-12. 2001..The strong correlation of DXR-BMD from the X-posure System with DXA at the wrist from the Hologic machine suggests that the X-posure System may be an alternative to DXA at the wrist for the assessment of osteoporosis... - Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research GroupD M Black
Department of Epidemiology and Biostatistics, University of California San Francisco, 94105, USA
J Bone Miner Res 14:821-8. 1999..Spinal radiographs identifying prevalent vertebral deformities may be a useful additional measurement to classify further a woman's risk of future fracture... - Epidemiology of fractures and assessment of fracture riskD M Black
Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
Clin Lab Med 20:439-53. 2000..Such populations will potentially derive maximal benefit from therapies and other strategies that reduce fracture risk... - Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research GroupD M Black
Department of Epidemiology and Biostatistics, University of California, San Francisco 94105, USA
J Clin Endocrinol Metab 85:4118-24. 2000..Furthermore, reduction in risk is evident early in the course of treatment. This pooled analysis provides a more precise estimate of the antifracture efficacy of alendronate in women with osteoporosis than that in prior reports... - Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialS R Cummings
Department of Epidemiology and Biostatistics, University of California, San Francisco 94105, USA
JAMA 280:2077-82. 1998..Alendronate sodium reduces fracture risk in postmenopausal women who have vertebral fractures, but its effects on fracture risk have not been studied for women without vertebral fractures... - Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetesAnn V Schwartz
Department of Epidemiology and Biostatistics, University of California San Francisco, 185 Berry St, Lobby 5, Ste 5700, San Francisco, CA 94107 1762, USA
JAMA 305:2184-92. 2011..It is not known if low BMD, central to fracture prediction in older adults, identifies fracture risk in patients with DM... - Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosisD C Bauer
Department of Medicine, University of California San Francisco Coordinating Center, 185 Berry 5700, San Francisco, CA 94107, USA
J Clin Endocrinol Metab 91:1370-5. 2006..Treatment of osteoporotic women with PTH increases biochemical markers of bone turnover, increases axial bone mineral density (BMD), and reduces fracture risk... - Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research GroupM C Nevitt
Department of Epidemiology and Biostatistics, University of California, San Francisco 94105, USA
Arch Intern Med 160:77-85. 2000..Women with new vertebral fractures have an increased risk of back pain and functional limitation because of back pain. Alendronate sodium treatment reduces the risk of new vertebral fracture by 50% in postmenopausal women with osteoporosis... - Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosisD E Sellmeyer
Department of Medicine Endocrinology, University of California San Francisco, San Francisco, CA, USA
Osteoporos Int 18:973-9. 2007..No baseline participant characteristic consistently predicted increased bone density response to PTH(1-84), although women with larger changes in 1,25 dihydroxyvitamin D during therapy had larger increases in BMD... - Vitamin D insufficiency does not affect response of bone mineral density to alendronateD M Antoniucci
Department of Medicine, San Francisco Department of Veterans Affairs Medical Center, University of California, San Francisco, CA 94121, USA
Osteoporos Int 20:1259-66. 2009..We found that vitamin D insufficiency is common among patients with low bone density but that vitamin D insufficiency did not impair response to alendronate... - Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scansTony M Keaveny
Department of Mechanical Engineering, University of California, Berkeley, California 94720 1740, USA
J Bone Miner Res 23:1974-82. 2008.... - Developing better economic models of osteoporosis: considerations for the calculation of the relative risk of fractureDennis M Black
UCSF Prevention Sciences Group, University of California-San Francisco, San Francisco, CA, USA
Value Health 9:54-8. 2006..CONCLUSION: It illustrates the importance of considering the prevalence of risk factors in the general population when calculating RR in a target population... - Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosisDiana M Antoniucci
Division of Endocrinology, Department of Medicine, University of California, San Francisco, California 94107, USA
J Clin Endocrinol Metab 92:942-7. 2007..The effect of PTH therapy on serum and urinary calcium levels and the risk of hypercalcemia or hypercalciuria has not been formally evaluated... - Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture TrialR Wustrack
Department of Epidemiology and Biostatistics, University of California, San Francisco, 185 Berry Street, Suite 5700, San Francisco, CA 94107, USA
Osteoporos Int 23:53-8. 2012..We found that prevalent and recent vertebral fractures strongly and independently predicted subsequent vertebral fractures including those which were severe... - Older women with diabetes have an increased risk of fracture: a prospective studyA V Schwartz
Department of Epidemiology, Division of Endocrinology, University of California San Francisco, San Francisco, California 94105, USA
J Clin Endocrinol Metab 86:32-8. 2001..This study indicates that diabetes is a risk factor for hip, proximal humerus, and foot fractures among older women, suggesting that fracture prevention efforts should be a consideration in the treatment of diabetes... - Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessmentSven Prevrhal
Department of Epidemiology and Biostatistics, University of California San Francisco, 185 Berry St, San Francisco, CA 94107, USA
Curr Med Res Opin 25:921-8. 2009..The objective of this study was to define the effect of teriparatide on the incidence of vertebral fractures defined by QM plus SQ assessment... - Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugsSteven R Cummings
Department of Medicine, University of California, San Francisco, California, USA
Am J Med 112:281-9. 2002..CONCLUSION: Improvement in spine bone mineral density during treatment with antiresorptive drugs accounts for a predictable but small part of the observed reduction in the risk of vertebral fracture... - Updated fracture incidence rates for the US version of FRAXB Ettinger
Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA, USA
Osteoporos Int 21:25-33. 2010..On the basis of updated fracture and mortality data, we recommend that the base population values used in the US version of FRAX be revised. The impact of suggested changes is likely to be a lowering of 10-year fracture probabilities... - Diffuse idiopathic skeletal hyperostosis (DISH): relation to vertebral fractures and bone densityG Diederichs
Department of Radiology and Biomedical Imaging, Musculoskeletal and Quantitative Imaging Research Group, University of California, China Basin Landing, 185 Berry Street, San Francisco, CA 94107, USA
Osteoporos Int 22:1789-97. 2011..Paravertebral calcifications should be considered in patients with DISH when interpreting BMD measurements because both dual X-ray absorptiometry (DXA) and quantitative CT (QCT) densitometry may not be reliable... - Circadian activity rhythms and mortality: the study of osteoporotic fracturesGregory J Tranah
California Pacific Medical Center Research Institute, San Francisco Coordinating Center, UCSF, 185 Berry Street, Lobby 4, Suite 5700, San Francisco, CA 94107, USA
J Am Geriatr Soc 58:282-91. 2010..To determine whether circadian activity rhythms are associated with mortality in community-dwelling older women... - Sex hormones and frailty in older men: the osteoporotic fractures in men (MrOS) studyPeggy M Cawthon
Research Institute, California Pacific Medical Center, San Francisco, California 94107 1728, USA
J Clin Endocrinol Metab 94:3806-15. 2009..As men age, the prevalence of frailty increases whereas levels of androgens decline. Little is known about the relation between these factors... - Comparison of DXA hip structural analysis with volumetric QCTSven Prevrhal
Department of Radiology, UCSF, San Francisco, CA 94107, USA
J Clin Densitom 11:232-6. 2008..5 for CSMI) and standard DXA at the neck (r2=0.82 for BMD). HSA and volumetric QCT compared favorably, which supports the validity of a projective technique such as DXA to derive geometrical properties of the proximal hip... - Pentosidine and increased fracture risk in older adults with type 2 diabetesAnn V Schwartz
Department of Epidemiology and Biostatistics, University of California, San Francisco, California 94107 1762, USA
J Clin Endocrinol Metab 94:2380-6. 2009..Type 2 diabetes is associated with higher fracture risk at a given bone mineral density. Advanced glycation endproducts (AGEs) accumulate in bone collagen with age and diabetes and may weaken bone... - Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trialAnn V Schwartz
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA
J Bone Miner Res 25:976-82. 2010..5 or less but does not reduce risk of NVF in women whose T-scores are greater than -2... - Fracture and the risk of coronary events in women with heart diseasePaul D Varosy
Department of Medicine, University of California, San Francisco 94143 0124, USA
Am J Med 115:196-202. 2003..Osteoporosis is associated with aortic calcification and cardiovascular mortality. However, whether skeletal fractures predict the risk of coronary events is unknown... - Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosisAnne L Schafer
Department of Medicine, University of California, San Francisco, CA 94115, USA
J Clin Densitom 14:68-73. 2011..The relationship between bone turnover marker and calcium responses to PTH(1-84) is modest and does not suggest a profound, broadly heightened responsiveness of certain individuals to therapy... - Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelinesMeghan G Donaldson
San Francisco Coordinating Center, California Pacific Medical Center, San Francisco, CA 94107, USA
J Bone Miner Res 25:1506-11. 2010..Application of the new NOF guidelines would result in recommending a very large proportion of white men in the United States for pharmacologic treatment of osteoporosis, for many of whom the efficacy of treatment is unknown... - Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trialDouglas C Bauer
Department of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, California 94107, USA
J Bone Miner Res 21:292-9. 2006..The nonspine fracture efficacy of alendronate was significantly greater among both osteoporotic and nonosteoporotic women with higher baseline levels of the bone formation marker PINP... - Alternative tree-structured survival analysis based on variance of survival timeHua Jin
Department of Radiology, The University of California at San Francisco, San Francisco, CA 94143 0946, USA
Med Decis Making 24:670-80. 2004..A limited simulation study suggests that the proposed algorithm is a competitive alternative to the log-rank or martingale residual-based TSSA approaches... - Diabetes and bone loss at the hip in older black and white adultsAnn V Schwartz
Department of Epidemiology and Biostatistics, University of California, San Francisco, California 94105, USA
J Bone Miner Res 20:596-603. 2005.... - Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trialDouglas C Bauer
Department of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, California 94105, USA
J Bone Miner Res 19:1250-8. 2004..In the alendronate group (n = 3105), greater reductions in one or more biochemical marker were associated with a lower risk of fracture... - Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trialsDouglas C Bauer
Department of Medicine, University of California, San Francisco 94105, USA
Arch Intern Med 164:146-52. 2004.... - Clinical use of bone densitometry: scientific reviewSteven R Cummings
The UCSF Coordinating Center, University of California, San Francisco, USA
JAMA 288:1889-97. 2002..Measurement of bone mass by densitometry is a primary part of diagnosing osteoporosis and deciding a preventive treatment course. Bone mineral densitometry has become more widely available and commonly used in practice... - Older women with diabetes have a higher risk of falls: a prospective studyAnn V Schwartz
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA
Diabetes Care 25:1749-54. 2002..To determine whether older women with diabetes have an increased risk of falls and whether known risk factors for falls account for any increased risk... - Vitamin D insufficiency does not affect bone mineral density response to raloxifeneDiana M Antoniucci
Division of Endocrinology, Department of Medicine, University of California, San Francisco, California 94143, USA
J Clin Endocrinol Metab 90:4566-72. 2005..Vitamin D insufficiency and osteoporosis are common and often coexist in postmenopausal women... - Serum 25-hydroxyvitamin D is unaffected by multiple freeze-thaw cyclesDiana M Antoniucci
Division of Endocrinology, Department of Medicine, University of California, San Francisco, CA 94105, USA
Clin Chem 51:258-61. 2005 - Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fracturesMichael C Nevitt
Department of Epidemiology and Biostatistics, University of California, San Francisco, California 94105, USA
J Bone Miner Res 20:131-40. 2005..Risk factors and low BMD should be useful to help focus efforts to prevent these fractures... - Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive menD Siegel
Department of Epidemiology and Biostatistics, University of California, San Francisco
JAMA 267:1083-9. 1992.... - Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation GuidelinesMeghan G Donaldson
San Francisco Coordinating Center, California Pacific Medical Center, San Francisco, California 94107, USA
J Bone Miner Res 24:675-80. 2009..Application of the new NOF Guidelines would result in recommending a very large proportion of white women in the United States for pharmacologic treatment of osteoporosis... - Hip fracture in women without osteoporosisStacey A Wainwright
Bone and Mineral Research Unit, Department of Medicine, Oregon Health and Science University, 3181 S W Sam Jackson Park Road, Mail Code CR113, Portland, Oregon 97239, USA
J Clin Endocrinol Metab 90:2787-93. 2005..These findings call attention to the many older women who suffer hip fracture but do not have particularly low antecedent BMD measures and help begin to identify risk factors associated with higher bone density levels... - Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapySomnath Sarkar
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
J Bone Miner Res 17:1-10. 2002..The present data show that the measured BMD changes observed with raloxifene therapy are poor predictors of vertebral fracture risk reduction with raloxifene therapy... - Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trialPierre D Delmas
University of Claude Bernard of Lyon, Hopital Edouard Herriot, Service de Rhumatologie et de Pathologie Osseuse, Lyon 69437, France
J Clin Endocrinol Metab 87:3609-17. 2002..The decreased vertebral fracture risk in yr 4 alone was not different from that observed in the first 3 yr... - Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fracturesMarc C Hochberg
University of Maryland School of Medicine, Baltimore, Maryland, USA
J Bone Miner Res 20:971-6. 2005..Analyses of data from 3658 postmenopausal women with osteoporosis enrolled in the Fracture Intervention Trial showed that alendronate is effective in reducing the risk of symptomatic osteoporotic fractures across a spectrum of ages... - What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa?Howard A Fink
Geriatric Research Education and Clinical Center, VA Medical Center, Minneapolis, Minnesota 55417, USA
J Bone Miner Res 20:1216-22. 2005..The proportion of deformities clinically diagnosed ranged from <15% for milder deformities to nearly 30% for more severe deformities... - Clinical use of bone densitometry: clinical applicationsDavid W Bates
Department of Medicine, Brigham and Women s Hospital, and the Center for Applied Medical Information Systems Research, Partners HealthCare Systems, and Harvard Medical School, Boston, Mass 02115, USA
JAMA 288:1898-900. 2002..Clinicians need better approaches for identifying patients most likely to benefit from screening, systems that facilitate their application, and test results that are easy to interpret... - Alendronate and atrial fibrillationSteven R Cummings
N Engl J Med 356:1895-6. 2007 - Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trialJohn A Kanis
WHO Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
Bone 33:293-300. 2003.... - Bone mineral density and prevalent vertebral fractures in men and womenJane A Cauley
Department of Epidemiology, University of Pittsburgh, 130 DeSoto Street, Crabtree Hall A524, Pittsburgh, PA 15261, USA
Osteoporos Int 15:32-7. 2004..Measures of bone mass that partially correct for gender differences in bone size may yield universal estimates of fracture risk. Prospective studies are needed to confirm this observation... - Identification of vertebral fracture and non-osteoporotic short vertebral height in men: the MrOS studyLynne Ferrar
Academic Unit of Bone Metabolism, University of Sheffield, United Kingdom
J Bone Miner Res 22:1434-41. 2007..Non-osteoporotic SVH may mimic VF but is excluded in ABQ. In men, this led to discordance between ABQ and other methods, but SVH was not linked to low bone density. Exclusion of SVH could reduce false positives... - Prevalent vertebral fractures in black women and white womenJane A Cauley
Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
J Bone Miner Res 23:1458-67. 2008..The prevalence of vertebral fractures is lower in black compared with white women but increases with age, low BMD, and number of risk factors... - Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention TrialSara A Quandt
Department of Public Health Sciences, Wake Forest University School of Medicine, Winston Salem, NC 25717 1063, USA
Mayo Clin Proc 80:343-9. 2005..6 and -2.5 at the femoral neck and to describe how soon after initiation of therapy alendronate becomes effective and whether it is consistent in women with and without existing radiographic vertebral fracture... - Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extensionKristine E Ensrud
Department of Medicine, VA Medical Center, Minneapolis, Minnesota 55417, USA
J Bone Miner Res 19:1259-69. 2004..However, among women who discontinued alendronate and took placebo in the extension, BMD remained higher, and reduction in bone turnover was greater than values at FIT baseline, showing persistence of alendronate's effects on bone... - beta-Blocker use, BMD, and fractures in the study of osteoporotic fracturesIan R Reid
Department of Medicine, University of Auckland, Auckland, New Zealand
J Bone Miner Res 20:613-8. 2005..We studied the association of beta-blocker use with BMD and fractures in the Study of Osteoporotic Fractures. beta-blocker use and BMD are unrelated in this cohort, and associations with fracture risk are inconsistent... - Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) StudyOlof Johnell
Department of Orthopaedics, , Malm, Sweden
J Bone Miner Res 19:764-72. 2004..006) and lower LS BMD values (p = 0.008) at baseline. These data suggest that the efficacy of raloxifene in reducing vertebral fractures is largely independent of the presence of clinical risk factors for osteoporotic fractures... - Vignettes in osteoporosis: a road map to successful therapeuticsClifford J Rosen
Maine Center for Osteoporosis Research and Education, St Joseph Hospital, Bangor, Maine 04401, USA
J Bone Miner Res 19:3-10. 2004..We describe five common clinical scenarios encountered in the practice of osteoporosis medicine and various road maps that could lead to successful therapy... - Classification algorithms for hip fracture prediction based on recursive partitioning methodsHua Jin
Department of Radiology University of California, San Francisco 94143-0946, USA
Med Decis Making 24:386-98. 2004..A dual X-ray absorptiometry hip scan and information from clinical examinations can identify subjects with elevated 5-year hip fracture risk without loss of efficiency to more costly and complicated algorithms... - Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fracturesEthel S Siris
Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
J Clin Endocrinol Metab 88:3482-6. 2003..A call to action is necessary to reduce the human and economic costs associated with this serious and treatable disease... - Review of comparative effectiveness of treatments to prevent fracturesDennis M Black
Ann Intern Med 148:885-6; author reply 887. 2008